Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.

Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H.

Breast Cancer Res Treat. 2013 Jan;137(2):373-82. doi: 10.1007/s10549-012-2346-4. Epub 2012 Dec 7.

2.

MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.

Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H.

Nat Commun. 2013;4:1393. doi: 10.1038/ncomms2393.

3.

MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.

Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY.

Breast Cancer Res Treat. 2012 Aug;134(3):1081-93. doi: 10.1007/s10549-012-2034-4. Epub 2012 Apr 4.

PMID:
22476851
4.

MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression.

Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobie PE, Zhu T.

PLoS One. 2012;7(8):e41523. doi: 10.1371/journal.pone.0041523. Epub 2012 Aug 2.

5.

miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer.

Yu J, Xie F, Bao X, Chen W, Xu Q.

Mol Cancer. 2014 May 24;13:121. doi: 10.1186/1476-4598-13-121.

6.

RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells.

Liu Z, Chen L, Zhang X, Xu X, Xing H, Zhang Y, Li W, Yu H, Zeng J, Jia J.

J Cell Mol Med. 2014 Apr;18(4):610-23. doi: 10.1111/jcmm.12209. Epub 2014 Jan 22.

7.

Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.

Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP, Santoni A, Bissell MJ, Nisticò P.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19280-5. doi: 10.1073/pnas.1214394109. Epub 2012 Nov 5.

8.

Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.

Yamasaki T, Seki N, Yamada Y, Yoshino H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Nakagawa M, Enokida H.

Int J Oncol. 2012 Sep;41(3):805-17. doi: 10.3892/ijo.2012.1543. Epub 2012 Jul 3.

9.

MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.

Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P, Fuxe J.

Oncogene. 2013 Dec 12;32(50):5614-24. doi: 10.1038/onc.2013.322. Epub 2013 Aug 19.

10.

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.

Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J.

Oncogene. 2011 Mar 24;30(12):1436-48. doi: 10.1038/onc.2010.509. Epub 2010 Nov 8.

PMID:
21057535
11.

Targets of miR-200c mediate suppression of cell motility and anoikis resistance.

Howe EN, Cochrane DR, Richer JK.

Breast Cancer Res. 2011 Apr 18;13(2):R45. doi: 10.1186/bcr2867.

12.
13.

Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN.

Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, Zhao L, Qu H, Fan Y, Wu C.

PLoS One. 2012;7(6):e39520. doi: 10.1371/journal.pone.0039520. Epub 2012 Jun 25.

14.

MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer.

Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, Cao DX, Chen GQ, He JR, Zhao Q.

Carcinogenesis. 2013 Mar;34(3):713-22. doi: 10.1093/carcin/bgs383. Epub 2012 Dec 17.

15.

Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells.

Ahmad A, Sarkar SH, Bitar B, Ali S, Aboukameel A, Sethi S, Li Y, Bao B, Kong D, Banerjee S, Padhye SB, Sarkar FH.

Mol Cancer Ther. 2012 Oct;11(10):2193-201. doi: 10.1158/1535-7163.MCT-12-0232-T. Epub 2012 Jul 19.

16.

Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells.

Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, Fan Y, Chen X, Wu C.

Mol Cell Biochem. 2012 Apr;363(1-2):427-36. doi: 10.1007/s11010-011-1195-5. Epub 2011 Dec 21.

PMID:
22187223
17.

MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.

Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ, Gregory PA, Khew-Goodall Y.

Oncogene. 2014 Jul 31;33(31):4077-88. doi: 10.1038/onc.2013.370. Epub 2013 Sep 16.

PMID:
24037528
18.

Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy.

Li Q, Song XW, Zou J, Wang GK, Kremneva E, Li XQ, Zhu N, Sun T, Lappalainen P, Yuan WJ, Qin YW, Jing Q.

J Cell Sci. 2010 Jul 15;123(Pt 14):2444-52. doi: 10.1242/jcs.067165. Epub 2010 Jun 22. Erratum in: J Cell Sci. 2010 Aug 1;123(Pt 15):2680.

19.

MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.

Hu Y, Zhu Q, Tang L.

PLoS One. 2014 Mar 17;9(3):e92099. doi: 10.1371/journal.pone.0092099. eCollection 2014.

20.

Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis.

Lei R, Tang J, Zhuang X, Deng R, Li G, Yu J, Liang Y, Xiao J, Wang HY, Yang Q, Hu G.

Oncogene. 2014 Mar 6;33(10):1287-96. doi: 10.1038/onc.2013.65. Epub 2013 Mar 11.

PMID:
23474751
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk